41. Ensure availability of DRV paediatric formulations in LMIC countries until DRVr FDC is available, and partner with GAP-f partners to develop transition plans to generic products once the generic FDC is available (expected in Q4 2020).
Johnson & Johnson through Janssen Pharmaceutical NV, part of its Janssen Pharmaceutical Companies, is working with PEPFAR on a catalytic procurement project for children in the developing world. The parties have agreed on the quantity of Darunavir 75 mg required to support the initiative for 2019/2020, as such manufacturing and shipments have commenced and product needs continue to be collected from countries. Q4 2019 and January 2020 orders have shipped, and additional bottles are ready to ship in February 2020. Open orders have also been placed for Q2-Q4 2020, and manufacturing is planning production needs accordingly.
To support Darunavir forecasting and production planning, the parties have agreed to share their respective pediatric demand/order forecast summaries with CHAI & the ARV Procurement Working Group (APWG). The first APWG forecast view was shared in January 2020, and has provided greater visibility to the collective pediatric Darunavir forecasted demand.
Since the last update, Q1 and Q2 2020 orders have shipped, and orders for Q3 and Q4 2020 will be postponed until Q3 and Q4 2021 due to insufficient demand from the countries. Johnson & Johnson production has planned accordingly, and PEPFAR HQ is working with countries to identify eligible patients.
To support Darunavir forecasting and production planning, the parties have agreed to share their respective pediatric demand/order forecast summaries with CHAI & the ARV Procurement Working Group (APWG). This has provided greater visibility to the collective pediatric Darunavir forecasted demand.
Pharmaceutical companies, SRAs, WHO Prequalification Programme (PQ) and NRAs commit to:
1. Accelerate the national drug registration process to enable registration of any ARV listed by WHO EOI in around 40 participating countries within 1 year by ensuring that:
FOR PRODUCTS WITH PQ APPROVAL:
Company submits for registration in countries requesting use of the CRP (based on PQ approval) and process completed within around 4-5 months (country decisions within 3 months, plus submission processing time)
FOR PRODUCTS THAT HAVE NOT YET RECEIVED PQ APPROVAL:
Company submits with USFDA for full approval or tentative approval and process completed within 6 months;
USFDA approval or tentative approval review shared with WHO for Collaborative Registration
Procedure-lite (CRP-lite), a pilot program at first allowing FDA to share up to 5 minimally redacted reviews.
Company submits for registration in countries requesting use of the CRP (based on WHO PQ, FDA (CRP-lite) or other SRA review) and process completed in around 4-5 months (country decisions within 3 months, plus submission processing time)
13. Share their methodological approaches to acceptability studies (including palatability and ease of administration) and contribute to a repository held by GAP-f partners to guide future investigation of acceptability for paediatric products.
14. Consider the use of the CRP for national registration of pediatric ARV products on PADO, Optimal formulary and Limited use lists.
15. Ensure all drug registration dossiers meet minimum requirements at the time of filing and that responses to specific queries are complete and provided in a timely manner
20. Manufacture new PADO priority pediatric ARV products “at risk” such that the new product is available for supply at time of approval/tentative approval/prequalification, including validation of manufacturing process during regulatory review.